The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Takuo Fujita - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the effects of Elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using sf 36
Journal of Bone and Mineral Metabolism, 2011Co-Authors: Takuo Fujita, Yoshio Fujii, Akimitsu Miyauchi, Mutsumi Ohue, Mikio Nakajima, Yasuyuki TakagiAbstract:Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis. In order to compare the effects of Elcatonin and risedronate on such pain, 20 units of Elcatonin was intramuscularly injected to 18 patients, and 5 mg of risedronate was orally administered daily to 20 others with similar backgrounds. Exercise-induced pain was analyzed by measuring the fall of skin impedance by electroalgometry (EAM), and subjective pain was recorded by a visual rating system (VRS) on a scale of 0 (no pain) to 100 (unbearable pain). In patients treated with Elcatonin, the mean EAM-estimated pain was significantly reduced after 4, 5 and 6 months of treatment, and the VRS score after 3, 5 and 6 months, indicating a significant analgesic effect. In the risedronate group, however, improvement was less remarkable. Two-way analysis of variance using pain as a dependent variable and treatment group and time as independent variables revealed a significantly greater effect of Elcatonin over risedronate on both the EAM and VRS scores, and the influence of treatment time on pain was indistinguishable between the two treatment groups. Effect of exercise load on pain was less on knee load than knee and spine load and spine load, but indistinguishable between the two groups. Changes in QOL were evaluated by the SF-36 system. Norm-based scoring showed significant improvements in 3 of 4 categories for Elcatonin and in 2 of 4 for risedronate, suggesting comparable effects on the physical aspects of QOL, whereas responses to emotionally and socially directed questions indicated significant improvements in all 4 categories for risedronate, but none for Elcatonin, suggesting a more physical than emotional component in Elcatonin effects compared to risedronate.
-
Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and Elcatonin, an eel carbocalcitonin.
Journal of bone and mineral metabolism, 1999Co-Authors: Takuo Fujita, Yoshio Fujii, Akimitsu Miyauchi, Yasuyuki TakagiAbstract:Thirty postmenopausal women with reduced bone mineral density were divided randomly into two groups based on the chronological sequence of their first visit to the Osteoporosis Clinic of Katsuragi Hospital. Group I was given 600 mg ipriflavone orally daily and group II was weekly injected intramuscularly with 20 units Elcatonin, Asu1–7 eel calcitonin (carbocalcitonin). Lumbar spine BMD was measured by dual-energy X-ray absorptiometry, and trabecular bone mineral density at the distal radius, cortical bone density, and relative cortical volume at the radial diaphysis by peripheral computed tomography before the beginning of the study and at the 4th, 8th, and 12th month. Markers of bone metabolism—serum total alkaline phosphatase, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase, osteocalcin, intact osteocalcin, PICP and ICTP, and urinary pyridinoline, deoxypyridinoline, and calcium/creatinine (Ca/Cr)—were also measured at the same interval. Plasma parathyroid hormone (PTH) and calcitonin (CT) were measured at the same time. Radial trabecular bone density showed a significantly higher rate of increase in group I (ipriflavone group) than in group II (Elcatonin group) at the 4th month, whereas lumbar spine BMD showed more pronounced increase in the Elcatonin group than in the ipriflavone group throughout the study period. Bone metabolism markers tended to decline in both groups. Total and intact osteocalcin showed a significant fall from the baseline throughout the study period only in the ipriflavone group. Urine pyridinoline and deoxypyridinoline showed a significant fall from the baseline at the 12th month only in the ipriflavone group. On comparing bone gainers with increase of lumbar spine BMD by 2% or more with bone losers with a decrease by 2% or more, only urine Ca/Cr was significantly different, lower in the former than in the latter, despite the general tendency for bone resorption markers to decrease in bone gainers and to increase in bone losers.
-
A three-year comparative trial in osteoporosis treatment : Effect of combined alfacalcidol and Elcatonin
Journal of Bone and Mineral Metabolism, 1997Co-Authors: Takuo Fujita, Yoshio Fujii, Bunrei Goto, Akimitsu Miyauchi, Yasuyuki TakagiAbstract:The effect of agents commonly used for osteoporosis treatment in Japan—calcium, alfacalcidol (1α-hydroxyvitamin D3), Elcatonin (eel calcitonin derivative), and an alfacalcidol-Elcatonin combination—on lumbar spine bone mineral density (BMD) was assessed in 136 subjects aged 51–83 years with various degrees of osteopenia or osteoporosis, divided into five groups approximately matched for age and BMD over a period of 3 years. Lumbar spine BMD decreased by about 3.5% without treatment but was maintained at approximately baseline level on Elcatonin. Oral administration of 900mg/day calcium as AAA Ca (active absorbable algae calcium) or 1μg/day alfacalcidol increased lumbar BMD by 4.5% or 3.7%, respectively, after 3 years. Combined use of alfacalcidol and Elcatonin was most effective, increasing the BMD by 8.0% after 3 years. Extremely low calcium and vitamin D intake in Japan with consequent low calcitonin secretion may be responsible for the favorable effects. Alfacalcidol, an active form of vitamin D, and Elcatonin acting through different mechanisms may act synergistically on bone to increase BMD.
-
treatment of established osteoporosis with 1α oh vitamin d3 and low dose intermittent Elcatonin eel calcitonin derivative
Journal of Bone and Mineral Metabolism, 1992Co-Authors: Takuo Fujita, Masaaki Fukase, Takao Shimada, Hironosuke YamamotoAbstract:In addition to estrogen widely used all over the world for the prevention of postmenopausal osteoporosis, calcitonin and vitamin D derivatives are commonly employed to treat established osteoporosis at higher age in Japan. In order to critically assess the usefulness of vitamin D derivatives and calcitonin alone or in combination on the advancement of vertebral deformity at higher age, 32 osteoporotic patients with vertebral deformity with the mean age of 79 were randomly divided into 4 groups with indistinguishable age and severity of the vertebral deformity. Group 1 served as the control without specific medications for osteoporosis. Group 2 was treated with 10 units Elcatonin (eel calcitonin derivative) injected intramuscularly twice a week. Group 3 was given 0.75 to 1.5µg/day 1α (OH) vitamin D3 orally. Group 4 was given a combination of treatments used in Groups 2 and 3. In the lateral X-ray film of the spine taken prior to the test and every 6 months thereafter, the shape of the vertebral body T8 through L4 was monitored by measuring the anterior, central and posterior heights. Decrease of the vertebral height ratio; anterior or middle height/posterior or adjacent intact posterior height, by more than 20% of the original value or from above to below 0.80 both appeared to be inhibited during administration of 1α (OH) vitamin D3. Such effect seems to be augmented by simultaneous administration of Elcatonin. Actual decrease of vertebral height ratio values and the per cent fall from the original value significantly less in Groups 3 and 4 than in Group 1. Development of vertebral deformity assessed by the changes of the vertebral height thus appears to decrease during treatment with 1α (OH) vitamin D3 especially together with calcitonin in established osteoporosis.
S K Fujimoto - One of the best experts on this subject based on the ideXlab platform.
-
Elcatonin-mediated contractile and relaxant responses in SHR femoral artery.
Acta pharmacologica Sinica, 2001Co-Authors: S. Fujimoto, S K FujimotoAbstract:AIM: To study the effect of repeated systemic injections of Elcatonin (a synthetic analog of eel calcitonin) on the responses of rat femoral artery preparation to vasoactive drugs and to determine subtypes of muscarinic cholinoceptors involved in acetylcholine (ACh)-induced vasorelaxation in Elcatonin-treated rats. METHODS: Spontaneously hypertensive rats (SHR) were treated sc with Elcatonin, 0.5 and 5 U/kg, 3 times a week for 2 weeks. Responses to vasoactive drugs were determined in helically cut strips of femoral arteries of these rats. Schild plot data for muscarinic cholinoceptor antagonists were obtained on these vascular strips, using ACh as an agonist. RESULTS: Elcatonin did not alter systemic blood pressure and contractile responses of the femoral artery to KCl, norepinephrine, 5-hydroxytryptamine, and prostaglandin F(2alpha). Elcatonin attenuated isoproterenol-induced relaxation, increased ACh- and ATP-induced relaxations, and did not change relaxant responses to sodium nitroprusside and cromakalim in the femoral artery. Nitro L-arginine in the combination with tetraethylammonium (or charybdotoxin) completely abolished the relaxant response to ACh in the control but not in the Elcatonin-treated arteries. The muscarinic cholinoceptor subtype involved in the ACh-induced relaxation was M3 in the Elcatonin-treated as well as control SHR. CONCLUSION: Elcatonin decreases beta-adrenoceptor-mediated relaxation and increases M(3) cholinoceptor-mediated relaxation in the SHR femoral artery. Although the ACh-induced relaxation is explained by stimulated releases of nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF) in the SHR artery, a NO-and EDHF-independent mechanism in addition to NO and EDHF is responsible for the response to ACh in the femoral artery from the Elcatonin-treated SHR.
Yasuyuki Takagi - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the effects of Elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using sf 36
Journal of Bone and Mineral Metabolism, 2011Co-Authors: Takuo Fujita, Yoshio Fujii, Akimitsu Miyauchi, Mutsumi Ohue, Mikio Nakajima, Yasuyuki TakagiAbstract:Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis. In order to compare the effects of Elcatonin and risedronate on such pain, 20 units of Elcatonin was intramuscularly injected to 18 patients, and 5 mg of risedronate was orally administered daily to 20 others with similar backgrounds. Exercise-induced pain was analyzed by measuring the fall of skin impedance by electroalgometry (EAM), and subjective pain was recorded by a visual rating system (VRS) on a scale of 0 (no pain) to 100 (unbearable pain). In patients treated with Elcatonin, the mean EAM-estimated pain was significantly reduced after 4, 5 and 6 months of treatment, and the VRS score after 3, 5 and 6 months, indicating a significant analgesic effect. In the risedronate group, however, improvement was less remarkable. Two-way analysis of variance using pain as a dependent variable and treatment group and time as independent variables revealed a significantly greater effect of Elcatonin over risedronate on both the EAM and VRS scores, and the influence of treatment time on pain was indistinguishable between the two treatment groups. Effect of exercise load on pain was less on knee load than knee and spine load and spine load, but indistinguishable between the two groups. Changes in QOL were evaluated by the SF-36 system. Norm-based scoring showed significant improvements in 3 of 4 categories for Elcatonin and in 2 of 4 for risedronate, suggesting comparable effects on the physical aspects of QOL, whereas responses to emotionally and socially directed questions indicated significant improvements in all 4 categories for risedronate, but none for Elcatonin, suggesting a more physical than emotional component in Elcatonin effects compared to risedronate.
-
Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and Elcatonin, an eel carbocalcitonin.
Journal of bone and mineral metabolism, 1999Co-Authors: Takuo Fujita, Yoshio Fujii, Akimitsu Miyauchi, Yasuyuki TakagiAbstract:Thirty postmenopausal women with reduced bone mineral density were divided randomly into two groups based on the chronological sequence of their first visit to the Osteoporosis Clinic of Katsuragi Hospital. Group I was given 600 mg ipriflavone orally daily and group II was weekly injected intramuscularly with 20 units Elcatonin, Asu1–7 eel calcitonin (carbocalcitonin). Lumbar spine BMD was measured by dual-energy X-ray absorptiometry, and trabecular bone mineral density at the distal radius, cortical bone density, and relative cortical volume at the radial diaphysis by peripheral computed tomography before the beginning of the study and at the 4th, 8th, and 12th month. Markers of bone metabolism—serum total alkaline phosphatase, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase, osteocalcin, intact osteocalcin, PICP and ICTP, and urinary pyridinoline, deoxypyridinoline, and calcium/creatinine (Ca/Cr)—were also measured at the same interval. Plasma parathyroid hormone (PTH) and calcitonin (CT) were measured at the same time. Radial trabecular bone density showed a significantly higher rate of increase in group I (ipriflavone group) than in group II (Elcatonin group) at the 4th month, whereas lumbar spine BMD showed more pronounced increase in the Elcatonin group than in the ipriflavone group throughout the study period. Bone metabolism markers tended to decline in both groups. Total and intact osteocalcin showed a significant fall from the baseline throughout the study period only in the ipriflavone group. Urine pyridinoline and deoxypyridinoline showed a significant fall from the baseline at the 12th month only in the ipriflavone group. On comparing bone gainers with increase of lumbar spine BMD by 2% or more with bone losers with a decrease by 2% or more, only urine Ca/Cr was significantly different, lower in the former than in the latter, despite the general tendency for bone resorption markers to decrease in bone gainers and to increase in bone losers.
-
A three-year comparative trial in osteoporosis treatment : Effect of combined alfacalcidol and Elcatonin
Journal of Bone and Mineral Metabolism, 1997Co-Authors: Takuo Fujita, Yoshio Fujii, Bunrei Goto, Akimitsu Miyauchi, Yasuyuki TakagiAbstract:The effect of agents commonly used for osteoporosis treatment in Japan—calcium, alfacalcidol (1α-hydroxyvitamin D3), Elcatonin (eel calcitonin derivative), and an alfacalcidol-Elcatonin combination—on lumbar spine bone mineral density (BMD) was assessed in 136 subjects aged 51–83 years with various degrees of osteopenia or osteoporosis, divided into five groups approximately matched for age and BMD over a period of 3 years. Lumbar spine BMD decreased by about 3.5% without treatment but was maintained at approximately baseline level on Elcatonin. Oral administration of 900mg/day calcium as AAA Ca (active absorbable algae calcium) or 1μg/day alfacalcidol increased lumbar BMD by 4.5% or 3.7%, respectively, after 3 years. Combined use of alfacalcidol and Elcatonin was most effective, increasing the BMD by 8.0% after 3 years. Extremely low calcium and vitamin D intake in Japan with consequent low calcitonin secretion may be responsible for the favorable effects. Alfacalcidol, an active form of vitamin D, and Elcatonin acting through different mechanisms may act synergistically on bone to increase BMD.
Kunio Ishii - One of the best experts on this subject based on the ideXlab platform.
-
vasodilator effects of Elcatonin a synthetic eel calcitonin on retinal blood vessels in rats
Biological & Pharmaceutical Bulletin, 2015Co-Authors: Asami Mori, Tsutomu Nakahara, Kenji Sakamoto, Hironori Suzawa, Kunio IshiiAbstract:The aim of this study was to examine the effects of Elcatonin, a synthetic derivative of eel calcitonin, on rat retinal blood vessels, and to determine how diabetes affects the retinal vascular responses. Ocular fundus images were captured with an original high-resolution digital fundus camera in vivo. The retinal vascular responses were evaluated by measuring the diameter of retinal blood vessels contained in the digital images. Both systemic blood pressure and heart rate were continuously recorded. Elcatonin increased the diameter of retinal blood vessels but decreased mean blood pressure in a dose-dependent manner, whereas it had no significant effect on heart rate. A diminished retinal vasodilator response and significant pressor response to Elcatonin were observed in rats injected intravenously with N(G)-nitro-L-arginine methyl ester, a nitric oxide (NO) synthase inhibitor. Intravitreal injection of indomethacin, a non-selective cyclooxygenase (COX) inhibitor, and SQ22536, an adenylyl cyclase inhibitor, markedly attenuated the vasodilator effects of Elcatonin on retinal blood vessels. The retinal vasodilator responses to Elcatonin were unaffected 2 weeks after the induction of diabetes by a combination of streptozotocin treatment and D-glucose feeding. These results suggest that Elcatonin dilates rat retinal blood vessels via NO- and COX-dependent mechanisms and that the adenylyl cyclase-adenosine 3',5'-cyclic monophosphate system plays a major role in the vasodilator mechanisms. The retinal vasodilatory effects of Elcatonin seem to be preserved at early stages of diabetes.
-
comparison of the effects of single doses of Elcatonin and pregabalin on oxaliplatin induced cold and mechanical allodynia in rats
Biological & Pharmaceutical Bulletin, 2014Co-Authors: Manahito Aoki, Asami Mori, Tsutomu Nakahara, Kenji Sakamoto, Yuki Kurauchi, Kunio IshiiAbstract:Oxaliplatin frequently causes peripheral neuropathy. Clinical studies have indicated that pregabalin ameliorates oxaliplatin-induced peripheral neuropathy. However, pregabalin frequently causes dizziness and somnolence. We previously reported that Elcatonin, a synthetic analog of eel calcitonin, attenuated oxaliplatin-induced cold and mechanical allodynia in rats. The aim of the present study was to compare the anti-allodynic effects of Elcatonin and pregabalin in the rats developing the oxaliplatin-induced neuropathy. Male Sprague-Dawley rats were treated with a single dose of oxaliplatin (6 mg/kg, intraperitoneally (i.p.)) to induce cold and mechanical allodynia. We assessed the effects of subcutaneous Elcatonin (20 U/kg) and oral pregabalin (30 mg/kg) on cold and mechanical allodynia by cold stimulation (8°C) to the hind paw of the rats and the von Frey test, respectively. Elcatonin reversed the effects of oxaliplatin-induced cold and mechanical allodynia in rats for a longer time period than pregabalin does. These results suggested that Elcatonin might be useful for the clinical treatment of oxaliplatin-induced neuropathy.
-
salmon calcitonin reduces oxaliplatin induced cold and mechanical allodynia in rats
Biological & Pharmaceutical Bulletin, 2013Co-Authors: Manahito Aoki, Asami Mori, Tsutomu Nakahara, Kenji Sakamoto, Kunio IshiiAbstract:Oxaliplatin is commonly used anti-cancer drugs, but it frequently causes peripheral neuropathic pain. Recently, we reported that Elcatonin, a synthetic analog of eel calcitonin, attenuated the oxaliplatin- and paclitaxel-induced cold and mechanical allodynia in rats. In the present study, we determined whether salmon calcitonin also had anti-allodynic effects on oxaliplatin-induced neuropathy in rats. The rats were treated with a single dose of oxaliplatin (6 mg/kg, intraperitoneally (i.p.)). Oxaliplatin resulted in cold and mechanical allodynia. We assessed the anti-allodynic effects of subcutaneously administered salmon calcitonin (20 U/kg/d) by cold stimulation (8°C) directly to the hind paw of the rats and by using the von Frey test. Salmon calcitonin almost completely reversed the effects of both cold and mechanical allodynia. These results suggest that salmon calcitonin is also useful for treatment of oxaliplatin-induced neuropathy clinically.
-
effect of synthetic eel calcitonin Elcatonin on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats
European Journal of Pharmacology, 2012Co-Authors: Manahito Aoki, Asami Mori, Tsutomu Nakahara, Kenji Sakamoto, Kunio IshiiAbstract:Abstract Oxaliplatin and paclitaxel are commonly used anti-cancer drugs, but they frequently cause peripheral neuropathic pain. In this study, we investigated the effect of Elcatonin, a synthetic eel calcitonin, on oxaliplatin- and paclitaxel-induced neuropathy in rats. The rats were treated with a single dose of oxaliplatin (6 mg/kg, i.p.) or repeated doses of paclitaxel (2 mg/kg, i.p.) on 4 alternate days. Both treatments resulted in cold and mechanical allodynia. We assessed the anti-allodynic effects of subcutaneously administered Elcatonin (20 U/kg/day) by using a newly developed method to provide cold stimulation (8 °C) directly to the hind paw of the rats and by using the von Frey test. Elcatonin almost completely reversed the effects of both cold and mechanical allodynia. To determine the mechanism of this anti-allodynic effect, we examined the effect of Elcatonin on neuropathy induced by intraplantar injection of two organic compounds: allyl isothiocyanate (1 nmol/paw), which activates transient receptor potential ankyrin-1 channels, and menthol (1.28 μmol/paw), which activates transient receptor potential ankyrin-1 and melastatin-8. Pre-administration of Elcatonin almost completely prevented cold and mechanical allodynia from being induced by both compounds. These results suggest that Elcatonin attenuates oxaliplatin- and paclitaxel-induced neuropathic pain by inhibiting the cellular signaling related to transient receptor potential ankyrin-1 and melastatin-8. Thus, we conclude that administration of Elcatonin may improve the quality of life of cancer patients receiving chemotherapy.
Yi No Kang - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Elcatonin in postmenopausal women with osteoporosis a systematic review with network meta analysis of randomized clinical trials
Osteoporosis International, 2019Co-Authors: W C Chen, E Y Lin, Yi No KangAbstract:The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of Elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of Elcatonin and safety in combination therapies of Elcatonin (C-E). Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is Elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of Elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they independently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-Elcatonin medications had comparable fracture rates and bone mineral density change. Yet, C-E (WMD, − 18.93; 95% CI, − 23.97 to − 13.89) and M-E (WMD, − 13.72; 95% CI, − 19.51 to − 7.94) had significantly lower pain score than non-Elcatonin medications. However, M-E (POR = 8.413, 95% CI, 2.031 to 34.859) and non-Elcatonin medication (Peto OR, 7.450; 95% CI, 1.479 to 37.530) had significantly higher complication rates than placebo. No evidence detected inconsistency and small study effect in this network model. Based on current evidence, C-E may be considered for treating postmenopausal osteoporosis because it benefits on pain relief and complications. Moreover, it shows comparable fracture rate and bone mineral density change as compared with anti-osteoporosis and calcium supplements. Nevertheless, further trials are needed to investigate formula and dosages of Elcatonin.